SuperTab® 40LL

Breaking through direct compression limits

We proudly introduce our latest specialty grade, SuperTab® 40LL. SuperTab® 40LL is the newest product in DFE Pharma’s extensive direct compression portfolio.

SuperTab® 40LL provides you the possibility to comfortably run highly dosed formulations (e.g. mini-tablets) through processing machines directly compressible; at high speed with good content uniformity. The synergistic behavior of anhydrous lactose and lactitol monohydrate, combined in an agglomerate, allows this soluble excipient to provide compaction previously only provided by insoluble, plastic materials such as microcrystalline cellulose.

SuperTab® 40LL is a soluble, highly compactable, highly flowable excipient. This is the result of agglomerating anhydrous lactose and lactitol monohydrate utilizing our innovative, patented (EP 1 851 344 B1) agglomeration technology (figure 1).

Scanning Electron Microscope (SEM) image of SuperTab® 40LL.

Anhydrous lactose & lactilol

  • SuperTab® 40LL is composed of (anhydrous) lactose (95% w/w) (USP-NF, Ph.Eur. and JP) and lactitol monohydrate (5% w/w) (Ph. Eur.).
  • Production location: DMV-Fonterra Excipients GmbH & Co.KG, Nörten Hardenberg, Germany.
  • Standard packaging size: 35kg HDPE drums, with a transparent, low density polyethylene inner liner.
  • Re-test: 6 months.

Ask our expert

Bastiaan Dickhoff
Senior Product Application Specialist

Ask our expert